Android Apple

Regeneron Gets European OK of Lymphoma Drug Ordspono

By MarketWatch   |   3 months ago
Regeneron Gets European OK of Lymphoma Drug Ordspono

Regeneron Pharmaceuticals received approval from the European Commission for Ordspono to treat certain patients with non-Hodgkin lymphoma subtypes. This is the first approval globally for Ordspono and its bispecific antibody platform.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.